{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:31:28Z","timestamp":1794483088765,"version":"4.9.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.isci.2026.117766","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:03:48Z","timestamp":1791576228000},"page":"117766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase 3 trial of GB-K02 pegfilgrastim biosimilar for preventing chemotherapy-induced neutropenia in breast cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Jinhai","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengxin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-8846","authenticated-orcid":false,"given":"Suofu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117766_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117766_bib2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.isci.2026.117766_bib3","first-page":"721","article-title":"Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.isci.2026.117766_bib4","first-page":"203","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.isci.2026.117766_bib5","article-title":"Platinum-based chemotherapy for early triple-negative breast cancer","volume":"2023","author":"Mason","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.isci.2026.117766_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","article-title":"G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review","volume":"15","author":"Campbell","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.isci.2026.117766_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-025-02716-2","article-title":"Efficacy and safety of dose-dense chemotherapy for early-stage breast cancer under prophylactic pegfilgrastim administration: a systematic review and meta-analysis from clinical practice guidelines for the use of G-CSF 2022","volume":"30","author":"Yokoe","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117766_bib8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/03007995.2019.1703665","article-title":"Prophylaxis of febrile neutropenia with colony-stimulating factors: the first 25 years","volume":"36","author":"Edelsberg","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.isci.2026.117766_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40259-020-00411-4","article-title":"Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure","volume":"34","author":"Cornes","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.isci.2026.117766_bib10","series-title":"Pegfilgrastim","author":"Patel","year":"2025"},{"key":"10.1016\/j.isci.2026.117766_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1613199","article-title":"The use of granulocyte colony-stimulating factors in the management of breast cancer patients","volume":"15","author":"Ba\u0142ata","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117766_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?","volume":"27","author":"Boccia","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117766_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/cncr.33917","article-title":"Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group","volume":"128","author":"Russell","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.117766_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12325-023-02703-x","article-title":"The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study","volume":"41","author":"Yang","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.isci.2026.117766_bib15","first-page":"113","article-title":"Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma","volume":"28","author":"Li","year":"2019","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.isci.2026.117766_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4143\/crt.2022.987","article-title":"Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies","volume":"55","author":"Moon","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.isci.2026.117766_bib17","doi-asserted-by":"crossref","first-page":"20242","DOI":"10.1002\/cam4.6519","article-title":"Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III","volume":"12","author":"Takano","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2026.117766_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-23258-7","article-title":"An open-label, randomized study comparing lipegfilgrastim with filgrastim in pediatric patients receiving chemotherapy for Ewing sarcoma or rhabdomyosarcoma","volume":"15","author":"Belogurova","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117766_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117446","article-title":"Marrow adipogenic lineage precursors (MALPs) facilitate bone marrow recovery after chemotherapy","volume":"195","author":"Wang","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.isci.2026.117766_bib20","article-title":"Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study","volume":"8","author":"Kowalyszyn","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.isci.2026.117766_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117766_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.578","article-title":"Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta\u00ae in healthy subjects: A randomized, double-blind trial","volume":"8","author":"Wynne","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.isci.2026.117766_bib23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2174\/1389450123666220408101152","article-title":"Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials","volume":"23","author":"Ali","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.isci.2026.117766_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-025-13736-6","article-title":"Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Cancer"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226031470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226031470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:26:30Z","timestamp":1794479190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226031470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589004226031470"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117766","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3 trial of GB-K02 pegfilgrastim biosimilar for preventing chemotherapy-induced neutropenia in breast cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117766"}}